{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268042","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.648210+00:00","generated_at":"2026-05-16T23:57:44.714698+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Monte Rosa reports Q3 net loss $27.1M; second Novartis deal with $120M upfront","bullets":["Net loss $27.1M vs $23.9M YoY; collaboration revenue $12.8M (vs $9.2M).","Second Novartis agreement: $120M upfront, total eligible up to $5.7B for immune-mediated disease degraders.","Phase 1 NEK7 MGD MRT-8102 enrolling; initial data including high-CVD risk cohort on track for H1 2026.","Cash $396.2M at Sept. 30; raised $23.9M net from October ATM; runway through 2028.","MRT-2359 mCRPC data by year-end; CDK2/cyclin E1 IND submission targeted for 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268042","json":"https://secwatch.observer/filing/0001193125-25-268042.json","markdown":"https://secwatch.observer/filing/0001193125-25-268042.md","text":"https://secwatch.observer/filing/0001193125-25-268042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000119312525268042/0001193125-25-268042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000119312525268042/glue-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:57:44.714698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}